Last reviewed · How we verify
NCT06550687: INFOGENE
Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.
NA trial testing Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis in All Types of Metastatic Solid Malignancy in 80 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Centre Georges Francois Leclerc |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | other |
| Enrollment | 80 |
| Start date | 19 September 2024 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis
Conditions studied
- All Types of Metastatic Solid Malignancy — all drugs for All Types of Metastatic Solid Malignancy →
- 1st-line Treatment — all drugs for 1st-line Treatment →
- Exome Analysis — all drugs for Exome Analysis →
- Active File EXOMA2 Study — all drugs for Active File EXOMA2 Study →
Sponsor
Centre Georges Francois Leclerc — full company profile →
Who can join
18 and older, any sex, with All Types of Metastatic Solid Malignancy or 1st-line Treatment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene study offers the opportunity to study patient-physician communication, to assess patient preferences with regard to different information modalities concerning theranostic exome analysis, and to reflect on information modalities to ensure optimal patient comprehension of the information provided. The qualitative cross-sectional study includes a dual observational and interventional component involving cancer patients. The patients will come from the EXOMA 2 active file at Dijon University Hospital and the CGFL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06550687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Georges Francois Leclerc trials
Trials by the same sponsor.
- NCT07575854 — A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenom · NA · not yet recruiting
- NCT07413627 — A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aero · NA · not yet recruiting
- NCT07376512 — Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis · not yet recruiting
- NCT07093593 — Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs · NA · not yet recruiting
- NCT06944548 — Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Me · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06550687 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Georges Francois Leclerc
- Last refreshed: 18 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06550687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing